ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA-ADRENOCEPTORS

Abstract: The present invention relates to phenethanolamine derivatives of formula (I) wherein R<1> represents an aryl group optionally substituted by one or more substituents selected from halogen, hydroxy, C1-6alkoxy, C1-6alkyl, nitro, cyano, hydroxymethyl and trifluoromethyl; R<2> represents hydrogen or C1-6alkyl; R<3> represents a group (A) where the ring is substituted by one to four further substituents selected from C1-6alkyl, halogen, trifluoromethyl, and C1-6alkoxy; or R<3> represents a group (B) where the aromatic ring is optionally substituted by up to three further substituents selected from C1-6alkyl, halogen, trifluoromethyl, and C1-6alkoxy; R<4> represents hydrogen, or C1-6alkyl; R<5> represents ZCH2CO2H wherein Z represents a bond, or O; Y represents (CH2)n where n is 1-3; and physiologically acceptable derivatives thereof; to processes for their preparation; and their use in the treatment of conditions susceptible of amelioration by an atypical beta-adrenoceptor agonist.

Description: ARYLETHANOLAMINE DERIVATIVES AND THEIR USE AS AGONISTS OF ATYPICAL BETA- ADRENOCEPTORS This invention relates to a new class of chemical compounds and to their use in medicine In particular, the invention concerns novel phenethanolamine derivatives, methods for their preparation pharmaceutical compositions containing them and their use as agonists at atypical beta-adrenoceptors (also known as beta-3- adrenoceptors) Such receptors have been described for example by J R S Arch et al , Nature, 309, 163-165 (1984), C Wilson et al , Eur J Pharmacol , 100, 309- 319 (1984), L J Emoπne et al , Science, 245, 1 118-1 121 (1989), and A Bianchetti et al Br J Pharmacol , 100, 831 -839 (1990) Phenethanolamine derivatives having activity at atypical beta-adrenoceptors are disclosed in, for example, European Patent Applications EP-A-0455006 and EP-A-0543662 Atypical beta-adrenoceptors belong to the family of adrenoceptors which mediate the physiological actions of the hormones adrenaline and noradrena ne Sub¬ types of the adrenoceptors, c_ι -, α 2 -, βi-, β 2 - and β 3 -(atypιcal) can be identified on the basis of their pharmacological properties and physiological effects Chemical agents which stimulate or block these receptors (but not β 3 ) are widely used in clinical medicine More recently, emphasis has been placed upon specific receptor selectivity in order to reduce side effects caused in part by interactions with other receptors Atypical beta-adrenoceptors are known to occur in adipose tissue and the gastrointestinal tract Atypical beta-adrenoceptor agonists have been found to be particularly useful as thermogenic anti-obesity agents and as anti-diabetic agents Compounds having atypical beta-adrenoceptor agonist activity have also been described as being useful in the treatment of hyperglycaemia, as animal growth promoters, as blood platelet aggregation inhibitors as positive inotropic agents and as antiatherosclerotic agents, and as being useful in the treatment of glaucoma We have now found a novel class of phenylethanolamine derivatives which act as agonists at atypical beta-adrenoceptors GB 9525177 3, which is the priority document for the present application, describes the syntheses of the compounds of the invention WO95/33724, which was unpublished at the priority date of the present application, describes the syntheses of compounds which are also of use as agonists at atypical beta-adrenoceptors The invention therefore provides, in a first aspect compounds of formula (I) OH (i) wherein R1 represents an aryl group optionally substituted by one or more substituents selected from halogen, hydroxy, C-μβalkoxy, Cι _ alkyl, nitro, cyano, hydroxymethyl and trifluoromethyl, R 2 represents hydrogen or Cι. 6 alkyl, R 3 represents a group A where the ring is substituted by one to four further substituents selected from C1. 6 alkyl, halogen, trifluoromethyl, and C.. 6 alkoxy, or R 3 represents a group B where the aromatic ring is optionally substituted by up to three further substituents selected from Cι. 6 alkyl, halogen, trifluoromethyl, and Cι. 6 alkoxy, R 4 represents hydrogen, or Cι- 6 alkyl, R 5 represents ZCH2CO2H wherein Z represents a bond, or 0, Y represents (CH 2 ) n where n is 1-3, and physiologically acceptable derivatives thereof Referring to the general formula (I), alkyl includes both straight and branched chain saturated hydrocarbon groups Similarly, alkoxy includes both straight and branched chain groups. Referring to the general formula (I), aryl includes monocyclic or bicyclic aromatic carbocychc groups such as phenyl and naphthyl Preferably R 1 represents phenyl optionally substituted by one, two or three substituents selected from halogen, hydroxy, Cι. 6 alkoxy, d. 6 alkyl, nitro, cyano, hydroxymethyl and trifluoromethyl More preferably R 1 represents phenyl substituted by a chlorine, fluorine or bromine atom or a methyl or trifluoromethyl group, which atom or group is preferably located in the meta position Most preferably R 1 represents phenyl substituted by a chlorine atom iocated in the meta position. R 2 is preferably hydrogen or methyl. Where R 3 is group A, preferred substituents are one or more groups selected from halogen, e.g. fluoro or chloro, methyl, trifluoromethyl, and methoxy. Where R 3 is group B, n is preferably 1 or 2 and the aromatic ring has no further substitution R 4 is preferably hydrogen or methyl. A preferred sub-class of compounds of formula (I) are those where R^ represents phenyl substituted by a chlorine atom iocated in the meta position, R^ represents hydrogen or methyl, R^ represents a group A and is substituted by one or more groups selected from halogen, methyl, trifluoromethyl, and methoxy, R^ represents hydrogen or methyl, R^ represents CH2CO2H, or physiologically acceptable derivatives thereof. It will be appreciated that the above compounds of formula (I) are optically active. The individual, isolated isomers and mixtures thereof, including racemates, are within the scope of the present invention. Particularly preferred compounds of formula (II) are those wherein the asymmetric carbon atoms in the -CH(OH)- group and the -CH(CH 3 )- group are in the (R)-confιguratιon Suitable compounds of formula (I) of the invention are, (1-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propyl}-2,3-dιhydro-1 H-ιndol-5- yl)-acetιc acid, (1-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propyl}-1 ,2,3,4-tetrahydro- quιnolιn-6-yl)-acetιc acid, (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2-methyl-phenyl)- acetic acid, (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-3-methyl-phenyl)- acetic acid, (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2-fluoro-phenyl)- acetic acid, (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-3-fluoro-phenyl)- acetic acid, (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2,3-dιfluoro- phenyl)-acetιc acid, (5-Chloro-4-{2R-[2-(3-chloro-phenyl)-2R-hydroxy-ethylamιno]-propylamιno}-2- methoxy-phenyl)-acetιc acid, (4-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-ethylamιno}-2-methyl-phenyl)- acetic acid, (4-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-ethylamιno}-2,3-dιfluoro-phenyl)- acetic acid, (4-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-ethylamιno}-2-trιfluoromethyl- phenyl)-acetιc acid, (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2,6-dιfluoro- phenyl)-acetιc acid, (4-{2-[2-(3-chloro-pheπyl)-2R-hydroxyl-ethylamιno]-ethylamιno}-2,3,6-tπfluoro- phenyl)-acetιc acid, (4-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2-tπfluoromethyl- phenyl)-acetιc acid, (4-{2R-[2-(3-Chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2,3,6-trιfluoro- phenyl)-acetιc acid, [2-Chloro-4(2-{[2-(3-chloro-phenyl)-2R-hydroxy-ethyl]-amιπo}-propylamιno)-phenyl]- acetic acid, [5-Chloro-4-(2R-{[2-(3-chloro-phenyl)-2R-hydroxy-ethyl]-amιno}-propylamιno)-2- methyl-phenyl]-acetιc acid, (4-{2R-[2-(3-Chloro-phenyl)-2R-hydroxy-ethylamιno]-propylamιno}-2,6-dιfluoro- phenoxy)-acetιc acid, (4-{2R-[2-(3-Chloro-phenyl)-2R-hydroxy-ethylamιno]-propylamιno}-3-trιfluoromethyl- phenyl)-acetιc acid, or a physiologically acceptable derivative thereof Preferred compounds of the invention include (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2,3-dιfluoro- phenyl)-acetιc acid, or a physiologically acceptable derivative thereof By "a physiologically acceptable derivative" is meant any physiologically acceptable salt, ester, or salt of such ester, of a compound of formula (I) or any other compound which, upon administration to the recipient, is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof It will be appreciated by those skilled in the art that the compounds of formula (I) may be modified to provide physiologically acceptable derivatives thereof at any of the functional groups in the compounds of formula (I) Of particular interest as such derivatives are compounds modified at the carboxyl function, hydroxyl functions or at ammo groups It will be appreciated by those skilled in the art that the physiologically acceptable derivatives of the compounds of formula (I) may be deπvatised at more than one position Preferred physiologically acceptable derivatives of the compounds of formula (I) are pharmaceutically acceptable salts thereof Pharmaceutically acceptable salts of the compounds of formula (I) include those derived from physiologically acceptable inorganic and organic acids and bases Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene- p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonιc and benzenesulphonic acids Other acids such as oxalic, while not in themselves physiologically acceptable may be useful in the preparation of salts useful as intermediates in obtaining compounds of the invention and their physiologically acceptable acid addition salts Salts derived from appropriate bases include alkali metal (e.g sodium), alkaline earth metal (e g magnesium), ammonium and NR 4 + (where R is Cι- 4 alkyl) salts The compounds of formula (I) act as agonists at atypical beta -adrenoceptors and as such are useful in the treatment of clinical conditions susceptible to amelioration by administration of an atypical beta-adrenoceptor agonist Such conditions include hyperglycaemia, obesity, hyperlipemia, irritable bowel syndrome and its associated pain, motility dysfunction, excessive gastrointestinal secretion, non-specific diarrhoea, neurogenic inflammation, regulation of intraocular pressure, triglyceπdemia, diabetes, e g non-insu n-dependent diabetes mellitus (NIDDM or Type II), such as obese NIDDM and non-obese NIDDM, diabetic complications such as retinopathy, nephropathy, neuropathy, cataracts, coronary heart diseases and arteriosclerosis, osteoporosis, and gastrointestinal disorders, particularly inflammatory gastrointestinal disorders Accordingly the present invention provides a method of treatment of a mammal, including man, suffering from condition susceptible of amelioration by an atypical beta-adrenoceptor agonist which method comprises administering to the subject an effective amount of a compound of general formula (I) or a physiologically acceptable derivative thereof References in this specification to treatment include prophylactic treatment as well as the alleviation of symptoms In a further aspect, the invention provides the use of a compound of general formula (I) or a physiologically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment of a condition susceptible of amelioration by an atypical beta-adrenoceptor agonist While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical formulation The invention thus further provides a pharmaceutical formulation comprising a compound of formula (I) or a physiologically acceptable derivative thereof together with one or more physiologically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients The carπer(s) or excιpιent(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof Thus the compounds for use according to the present invention may be formulated for oral, buccal, parenteral, rectal or transdermal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or the nose) For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e g pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose) fillers (e g lactose, microcrystalline cellulose or calcium hydrogen phosphate), lubricants (e g magnesium stearate, talc or silica), dismtegrants (e g potato starch or sodium starch glycollate), or wetting agents (e g sodium lauryl sulphate) The tablets may be coated by methods well known in the art Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e g sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e g lecithin or acacia), non-aqueous vehicles (e g almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), and preservatives (e g methyl or propyl-β-hydroxybeπzoates or sorbic acid) The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate Preparations for oral administration may be suitably formulated to give controlled release of the active compound For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner The compounds according to the present invention may be formulated for parenteral administration by injection e g by bolus injection or continuous infusion Formulations for injection may be presented in unit dosage form e g in ampoules or in multi-dose containers, with an added preservative The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e g sterile pyrogen-free water, before use The compounds according to the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, e g containing conventional suppository bases such as cocoa butter or other glyceπdes In addition to the formulations described previously, the compounds may also be formulated as a depot preparation Such long acting formulations may be administered by implantation (for example subcutaneously, transcutaneously or intramuscularly) or by intramuscular injection Thus, for example, the compounds according to the present invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emuision in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt A proposed dose of the compounds according to the present invention for administration to a human (of approximately 70kg body weight) is 0 1 mg to 1g, preferably to 1 mg to 100mg of the active ingredient per unit dose, expressed as the weight of free base The unit dose may be administered, for example, 1 to 4 times per day The dose will depend on the route of administration It will be appreciated that it may be necessary to make routine variations to the dosage depending on the age and weight of the patient as well as the seventy of the condition to be treated The precise dose and route of administration will ultimately be at the discretion of the attendant physician or veterinarian The compounds of the invention may be prepared by any of the processes known in the art for the preparation of similar compounds For example, according to process (A), compounds of formula (I) may be prepared by reaction of a compound of formula (la) ,2 R 1 . R 3 N R a R (la) wherein R 1 , R 2 , and, are as defined as for formula (I), R 3 represents R 3 where the acidic group is protected by an alkyl ester, and R a and R are protecting groups, by deprotection of the protecting groups in a suitable mixture such as 6M hydrochloric acid in tetrahydrofuran According to process (B), compounds of formula (I) may be prepared by reaction of a compound of formula (II) with a compound of formula (III) wherein R 1 , R , R ,R a , and R are as defined above, in the presence of a reducing agent, followed by removal of the protecting groups Compounds of formula (II) may be prepared by reaction of compounds of formula (IV), with an amine acid salt of formula (V) (IV) (V) wherein R 1 , R 2 , and R b are as defined herein before, and R c is a suitable alkyl group for protection, in the presence of a reducing agent Following protection of the nitrogen, the ester is reduced by a suitable reducing agent such as di-isobutyl aluminium hydride Where R 3 is group A, compounds of formula (III) may be prepared from compounds of formula (VI) where the aromatic ring is optionally substituted as defined for R^, by treatment with a mixed ester, e g methyl, benzyl, of malonic acid at elevated temperature in a suitable solvent such as N,N dimethylformamide, followed by treatment with a suitable reducing agent Suitable reducing agents of use in the reactions include hydrogen in the presence of a catalyst, such as a noble metal catalyst, for example palladium, platinum or platinum oxide, Raney-nickel or hydride reducing agents such as borohydrides, for example sodium borohydride sodium triacetoxyborohydride or sodium cyanoborohydπde Suitable reaction conditions will be readily apparent to those skilled in the art and are further illustrated by the accompanying examples Compounds of formula (III) where R^ represents group B, (IV), (V) and (VI) are known compounds or may be prepared from known compounds by standard procedures well known to those skilled in the art The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner See for example 'Protective Groups in Organic Chemistry 1 Ed J F W McOmie (Plenum Press 1973) or 'Protective Groups in Organic Synthesis' by Theodora W Greene and P M G Wuts (John Wiley and Sons 1991 ) Conventional ammo protecting groups may include for example aralkyl groups, such as benzyl, diphenylmethyl or triphenylmethyl groups and acyl groups such as N- benzyloxycarbonyl or t-butoxycarbonyl Conventional oxygen protecting groups may include for example alky silyl groups, such as tπmethylsilyl, or tert-butyldimethylsilyl, alkylethers such as tetrahydropyranyl, or tert-butyl, or esters such as acetate Removal of any protecting groups present may be achieved by conventional procedures Atypical beta-adrenoceptor agonists are compounds which demonstrate a pharmacological response mediated at atypical beta-adrenoceptors This activity has been be measured as the ability to stimulate lipolysis by rat adipocytes at sub- micromolar concentrations, in a response that is resistant to blockade by standard beta-adrenoceptor blocking drugs such as propranolol A particularly useful method for determining agomst activity at human atypical beta- adrenoceptors involves the use of Chinese hamster ovarian (CHO) cells transfected with the human beta-3-adrenoceptor according to Method 2 The cell lines may also be transfected with human beta-1- and beta-2- adrenoceptor in a similar manner to provide a method of determining the selectivity of the compounds of the invention at the three receptors Method 1 Cell culture General cell culture guidelines are observed (Fershney, R A (1987) Culture of animal cells A manual of basic technique Wiley-Liss, Inc , N Y ) A standard cell culture incubator is used (37°C, 5% CO 2 in air, 95% relative humidity) H β 3 CHO cells are grown in 75ml flasks in MEMα medium containing 9% FCS & 125μg/ml G418 One confluent flask of cells is tryps ised and resuspended in 80ml of culture medium, 1 ml of the cell suspension is added to each well of three 24-well plates The plates are then incubated for 1 day Experimental method: The medium is aspirated from each well, and the well rinsed with phosphate- buffered saline (PBS, this is then aspirated). 1 ml of MEMα (no FCS or G418, 300μ M IBMX) is added to each well. Antagonists, if required, are added at this stage. The plate is then placed back in the incubator for 30mιn Drugs are then added to the wells (10μl, 100x required final concentration), the plate gently swirled to mix the drugs, and the plate placed back in the incubator for 30 m . The medium is then aspirated from each well, the well rinsed with PBS, and 0.5ml perchloric acid (6% v/v in distilled water, 2-5°C). The plate is left on ice for 30mιn. The perchloric acid (containing cAMP) is transferred to a clean 24-well plate and the acid neutralised by addition of saturated KHC0 3 solution (200μl) to each well The plate is then swirled and frozen (-20°C) until cAMP is assayed. cAMP is assayed using an enzyme- immunoassay kit (Amersham). The relative potency of each test agonist (EPMR) is compared to isoprenaline as follows: EC 5 o agonist EPMR = EC 50 isoprenaline wherein EC 50 is the molar concentration of agonist which produces 50% of the maximum possible response for that agonist. Using the non-selective beta-adrenoceptor agonist isoprenaline as a reference agonist, compounds selective for atypical beta-adrenoceptors should preferably be a minimum of 10-30 times less potent than isoprenaline at Q>ι- or β 2 -adrenoceptors and, more preferably, 300-1000 times less potent than isoprenaline at βi- or β 2 - adrenoceptors. An experimental model in which atypical beta-adrenoceptor agonists may be shown to be of use in the treatment of gastrointestinal disorders is described below as Method 3. The procedure is based upon that described by H Satoh et al., Gastroenterology, 8_1, 719-725 (1981 ) in which the effect of compounds on indomethacin-induced gastric antral lesions in the re-fed rat is investigated. Indomethacin is an example of the class of compound known as non-steroidal anti- inflammatory drugs (NSAIDs), the use of which is frequently associated with gastrointestinal ulcers Method 2 Food (but not water) is withheld from female random hooded rats (70-120g) for 24 hours and then the rats are re-fed with Rat and Mouse No 1 Maintenance Diet After 1 hour of access to food, the rats are dosed orally with either the test compound or solvent (0 5% w/v methyl cellulose in water) 30 minutes later, indomethacin (60mg/kg, dissolved in 1 % w/v NaHC0 3 in saline) is administered as a single subcutaneous injection at the back of the neck Subsequently, the rats are allowed food, but water is withheld, and the animals are humanely killed by cervical dislocation at 6 hours post dose Control animals received a single subcutaneous dose of the appropriate solvent The rat's stomach is removed (with a small amount of duodenum attached), opened along the greater curvature and the contents removed by washing with 0 9% w/v sodium chloride solution (saline) The opened stomach is pinned out (mucosal surface uppermost) on a polystyrene mat and the area of damage assessed by placing a grid (composed of 1 mm squares) over the antral region Antral damage appears as discrete black or dark brown ulcers The total area of antral damage is then expressed as a percentage of the total surface area of the antrum The protective effect of the test compound on indomethacin-induced antral damage is calculated as a percentage using the following equation % area of damage NSAID - %area of damage NSAID + test compound 100 x % area of damage with NSAID The invention is further illustrated by the following intermediates and examples All temperatures are in degrees centigrade Intermediate 1 (R -(3-chloro-phenyl)-hvdroxy-acetιc acid methyl ester A solution of (R)-(3-chloro-phenyl)-hydroxy-acetιc acid (19 98g) in methanol (250ml) containing concentrated sulphuric acid (1 ml) was heated under reflux for 6 5h The solution was cooled, neutralised with aqueous sodium bicarbonate solution, and concentrated The residue was dissolved in ethyl acetate, washed with aqueous sodium bicarbonate solution, dried, and evaporated to give the title compound (21 13g) as a pale-yellow oil [a] D -104° (c 1 00 MeOH) Intermediate 2 (RH3-chloro-phenyl)-(tert-butyl-dιmethyl-sιlanoxy)-acetιc acid methyl ester A solution of (R)-(3-chloro-phenyl)-hydroxy-acetιc acid methyl ester (21 0g), imidazole (14 25g), and tert-butyldimethylsilyl chloride (25 Og) in N,N- dimethylformamide (250ml) was stirred at room temperature for 18h The mixture was poured into water (2 51) and extracted with ethyl acetate The combined extracts were washed with water and saturated brine, dried, and concentrated The residue was purified by flash chromatography, eluting with cyclohexane ethyl acetate (9 1 ) to give the title compound as a colourless oil (32 63g) [a] D -55 4° (c 1 21 MeOH) ntermediate 3 (RH3-chloro-phenyl)-(tert-butyl-dιmethyl-sιlanoxy)-acetaldehyde To a stirred solution of (R)-(3-chloro-phenyl)-(tert-butyl-dιmethyl-sιlanoxy)-acetιc acid methyl ester (4 Og) in anhydrous ether (10ml) and maintained at <-65° was added dropwise a 1 5M solution of di-isobututylaluminium hydride in toluene (10ml) When addition was complete the solution was stirred at -65° for a further hour, then quenched with methanol (10ml) The mixture was allowed to attain room temperature when silica (20g) was added Solvent was removed under reduced pressure, and the residue was purified by flash chromatography, eluting with cyclohexane ethyl acetate (9 1 ) to give the title compound as a colourless liquid (3 1g) [a] D -45.3° (c 1 50 MeOH) Intermediate 4 2R-r2R-(tert-Butyl-d]methyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethylamιnol-propιonic acid methyl ester (R)-(3-chloro-phenyl)-(tert-butyl-dιmethyl-silanoxy)-acetaldehyde (2.32g) was added to a stirred solution of (R)-2-amιnopropιonιc acid methyl ester hydrochloride (1.13g) in dichloromethane (50ml) The solution was stirred for 15mιn, then sodium tπactetoxyborohydπde (3 45g) was added, and the mixture was stirred a further 18h The solution was washed with aqueous sodium bicarbonate solution, then the organic phase was dried and concentrated The residue was purified by chromatography, eluting with cyclohexane:ethyl acetate (9: 1 ) to give the title compound as a colourless oil (2.42g) [a] D -29 4° (c 1.36 MeOH) Similarly prepared was. Intermediate 5 [2R-(tert-Butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethylamιnol-acetιc acid methyl ester as a colourless oil (1 26g), Assay: Found: C 56.9; H 7.95, N 3.9% C 17 H 2 _CINO 3 Si requires C 57 1 , H 7.8; N 3.9% from amino-acetic acid methyl ester hydrochloride (1.05g) and (R)-(3-chloro- phenyl)-(tert-butyl-dιmethyl-silanoxy)-acetaldehyde (2.16g). Intermediate 6 (2R-(tert-Butoxycarbonyl)-f2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenvO- ethyll-aminoj-propionic acid methyl ester A mixture of 2R-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethylamιno]- propionic acid methyl ester (2 15g) and di-t-butyl pyrocarbonate (1 37g) was heated at 80-100° for 1 h The mixture was cooled and purified by chromatography eluting with cyclohexane ethyl acetate (19 1 ) to give the title compound as a colourless oil (2 70g) Assay Found C 58 4, H 8 1 , N 3 0% C 23 H 38 CINO 5 Sι requires C 58 5, H 8 1 , N 3 0% Similarly prepared was Intermediate 7 {(tert-Butoxycarbonyl)-r2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethvn- amιno)-acetιc acid methyl ester as a colourless oil (1 55g) from [2R-(tert-butyl- dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethylamιno]-acetιc acid methyl ester (1 20g) [a] D -25 2° (c 1 3 MeOH) Intermediate 8 (2R-(tert-ButoxycarbonylH2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)- ethyll-aminol-propionaldehyde 1 5M di-isobutylaluminium hydride in toluene (8 1 ml) was added dropwise to a stirred, cooled solution of the {2R-(tert-butoxycarbonyl)-[2R-(tert-butyl-dιmethyl- sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]-amιno}-propιonιc acid methyl ester (2 30g) in toluene (50ml) at such a rate that the reaction temperature did not rise above -70° The solution was stirred 1 h at this temperature, then quenched with methanol (10ml) The mixture was preabsorbed on silica and purified by chromatography eluting with cyclohexane ethyl acetate (9 1 ) to give the title compound as a colourless oil (1 45g) C 22 H 36 CINO 4 S1 MH + 443 Similarly prepared was Intermediate 9 ((tert-Butoxycarbonyl)-f2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethvπ- amιno)-acetaldehyde as a colourless gum (0 37g), n m r (CDCI 3 ) d -0 15 (d, 3H), 0 05 (d, 3H), 0 90 (s, 9H), 1 45 (d, 9H), 2 9-3 2 (m, 1 H), 3 4-3 65 (m, 1 H), 3 70 (s, 3H), 3 75-4 15 (m, 2H), 4 8-5 0 (m, 1 H), 7 05-7 35 (m, 4H) from {(tert-butoxycarboπyl)-[2R-(tert-butyl-dιmethyl-sιtanyloxy)-2-(3-chlorophenyl)- ethyl]-amιno}-acetιc acid methyl ester (0 50g) Intermediate 10 (2,3-Dιhydro-1 H-ιndol-5-yl)-acetιc acid methyl ester A suspension of (1 -acetyl-2,3-dιhydro-1 H-ιndol-5-yl)-acetιc acid methyl ester (0 60g) in 2M hydrochloric acid (15ml) was heated under reflux for 5h The mixture was evaporated to dryness The residue was dissolved in methanol (20ml) and treated with concentrated sulphuric acid (5 drops) The solution was stirred at room temperature for one hour, then concentrated The residue was partitioned between ethyl acetate and sodium carbonate solution The organic phase was dried and evaporated and the residue purified by chromatography eluting with cyclohexane ethyl acetate (2 1 ) to give the title compound as a brown oil (0 40g) Assay Found C 68 9, H 6 6, N 7 2% C 1 1 H 13 NO 2 requires C 69 1 , H 6 8, N 7 3% Intermediate 11 ,4-Amιno-2-methyl-phenyl)-acetιc acid methyl ester Sodium hydride (1 29g of 60% dispersion in oil) was added portionwise to a stirred solution of malonic acid, methyl benzyl ester (5 84ml) in dry N,N-dιmethylformamιde (40 ml) After 2 5h 2-fluoro-5-nιtro-tolueπe (5 Og) was added, and the mixture was warmed to 100° for 18h The mixture was cooled then partioned between ethyl acetate and water The aqueous phase was separated and extracted further with ethyl acetate The combined organic extracts were dried, concentrated, and purified by chromatography eluting with cyclohexane ethyl acetate (6 1 ) to give 2-(2-methyl- 4-nιtro-phenyl)-malonιc acid benzyl ester methyl ester, admixed with the starting malonate ester, as a yellow oil (4 60g) The crude mixture (4 2g), ammonium formate (7 1 g), and 10% palladium on carbon (0 45g) in methanol (150ml) was heated under reflux for 2h under an atmosphere of nitrogen The mixture was cooled, filtered, and the filtrate was concentrated Chromatography of the residue eluting with cyclohexane ethyl acetate (2 1) gave the title compound (1 55g) as a yellow oil Assay Found C 66 55, H 7 6, N 7 6% Cι 0 H 13 NO 2 requires C 67 0, H 7 3, N 7 8% n m r (CDCI 3 ) d values include 2 22 (s, 3H), 3 55 (s, 2H), 3 59 (broad s, 2H), 3 68 (s, 3H), 6 51 (s + d 2H), 6 98 (d, 1 H) Similarly prepared were Intermediate 12 (4-Amιno-3-methyl-phenyl)-acetιc acid methyl ester as a pale brown oil (0 901 g), n m r (CDCI 3 ) d values include 2 12 (s, 3H), 3 49 (s, 2H), 3 58 (broad s, 2H), 3 66 (s, 3H), 6 60 (d, 1 H), 6 92 (s + d, 2H) from 5-fluoro-2-nιtrotoluene (2 5g) and malonic acid, benzyl ester methyl ester (5 84ml) Intermediate 13 (4-Amιno-2-fluoro-phenyl,-acetιc acid methyl ester as a pale brown oil (1 43g) n m r (CDCI 3 ) d values include 3 57 (s, 2H), 3 74 (broad s, 2H), 3 69 (s, 3H), 6 32- 6 49 (m, 2H), 7 00 (t, 1 H) from 3,4-dιfluoro-nιtrobenzene (3 48ml) and malonic acid, benzyl ester methyl ester (5 69ml) Intermediate 14 (4-Amιno-3-fluoro-phenyl)-acetιc acid methyl ester as a yellow oil (0 34g) n m r (CDCI 3 ) d values include 3 50 (s, 2H), 3 69 (s, 3H), 6 66-6 90 (m, 3H) from 2,4-dιfluoro-nιtrobenzene (3 33ml) and malonic acid, benzyl ester methyl ester (6 0ml) Intermediate 15 (4-Amιno-2,3-dιfluor o-phenyl)-acetιc acid methyl ester as a pale yellow oil (1 08g), n m r (CDCI 3 ) d values include 3 59 (s, 2H), 3 71 (s, 3H), 3 80 (broad s, 2H), 6 50 (t, 1 H), 6 78 (t, 1 H) from 2,3,4-tπfluoro-nιtrobenzene (3 59ml) and malonic acid, benzyl ester methyl ester (5 69ml) Intermediate 16 (4-Amιno-2,3,6-tπfluoro-phenyl)-acetιc acid methyl ester as colourless crystals (1 35g) n m r (CDCI 3 ) d values include 3 72 (s, 3H), 3 60 (s, 2H), 6 30 (m, 1 H) from 2,3,4,6-tetrafluoro-nιtrobenzene (3 23g) and malonic acid, benzyl ester methyl ester (3 63g) Intermediate 17 (4-Amιno-2-bromo-phenyl)-acetιc acid methyl ester as a yellow oil (0 104g) n m r (CDCI 3 ) d values include 3 69 (s, 2H), 3 71 (s, 3H), 6 59 (dd, 1 H), 6 86 (m, 1 H), 7 06 (d, 1 H), from 3-bromo-4-fluoro-nιtrobenzene (6 91g) and malonic acid, benzyl ester methyl ester (5 69ml) Intermediate 18 (4-Amιno-2-tnfluoromethyl-phenyl)-acetιc acid methyl ester A solution of (4-amιπo-2-trιfluoromethyl-phenyl)-acetιc acid (0 082g) in methanol (10ml) containing concentrated sulphuric acid (0 1 ml) was heated under reflux for 2h The solution was cooled, concentrated, and partitioned between ethyl acetate and aqueous sodium carbonate solution The organic phase was separated, dried, and concentrated to give the title compound as a yellow solid (0 089g) C 10 H1 0 F3NO 2 MH + 234 Intermediate 19 f1-(2-(tert-Butoxycarbonyl-r2R-(tert-butyl-dιmethyl-sιlanoxy)-2-(3-chloro-phenyl)- ethyl]-amιno)-propyl)-2,3-dιhvdro-1 H-ιndol-5-vn-acetιc acid methyl ester A solution of (2,3-dιhydro-1 H-ιndol-5-yl)-acetιc acid methyl ester (0 10g) and {2R- (tert-butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyioxy)-2-(3-chloro-phenyl)-ethyl]- amιno}-propιonaldehyde (0.20g) in dichloromethane (15mi) containing acetic acid (0 031ml) was stirred at room temperature for 40 mm, then the reaction mixture was cooled to 0°, and sodium triacetoxyborohydride (0 19g) was added The mixture was stirred at room temperature for two days, then washed with aqueous sodium bicarbonate solution The organic phase was dried, concentrated, and the residue purified by chromatography eluting with cyclohexane ethyl acetate (9 1 ) to give the title compound as a yellow gum (0 22g) Assay Found C 64 1 , H 7 6, N 4 4% C 33 H 49 CIN 2 O 5 requires C 64 2, H 7 95, N 4 5% Chiral HPLC and π m r confirm the compound to be a mixture of RR and RS isomers (1 1 ) Similarly prepared were Intermediate 20 [1-(2-(tert-Butoxycarbonyl-[2R-(tert-butyl-dιmethyl-sιlanoxy)-2-(3-chloro-phenyl)- ethyl.-amino,-propyl)-1 ,2,3,4-tetrahydro-quinolin-6-yl ,-acetic acid methyl ester as a yellow oil (0 51g) n m r (CDCI 3 ) d values include 0 88 (s, 9H), 3 46 (s, 2H), 3 67 (s, 3H), 6 84 (broad s, 1 H), 6 91 (d, 2H), C 34 H 51 CIN 2 θ 5 Sι MH + 631 from (1 ,2,3,4-tetrahydro-quιnolιπ-6-yl)-acetιc acid methyl ester (0 20g) and {2R-(tert- butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- amιno}-propιonaidehyde (0 55g) Intermediate 21 [4-(2-{tert-Butoxycarbonyl-f2-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)- ethvπ-amιno,-propylamιno)-2-methyl-phenyll-acetιc acid methyl ester as a pale yellow oil (0.22g), Assay Found C 63 2, H 8 6, N 4 7% C 32 H 49 CIN 2 O 5 S1 requires C 63 5, H 8 2, N 4 6% from 4-amιno-2-methyl-pheπylacetιc acid methyl ester (0 11 g) and {2R-(tert- butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- amιπo}-propιonaldehyde (0 25g) Intermediate 22 f4-(2R-ftert-Butoxycarbonyl-r2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-f3-chloro-phenyl)- ethyll-amino}-propylamino)-3-methyl-phenyll-acetic acid methyl ester as a pale yellow gum (0 25g), Assay Found C 63 4, H 8 2, N 4 45% C 32 H 49 CIN 2 O 5 S1 requires C 63 5, H 8 2, N 4 6% from 4-amιno-3-methylphenyl-acetιc acid methyl ester (0 10g) and {2R-(tert- butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- amιno}-propιonaldehyde (0 25g) Intermediate 23 f4-(2R-(tert-Butoxycarbonyl-f2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)- ethyl1-amιno)-propylamιno)-2-fluoro-phenyll-acetιc acid methyl ester as a colourless oιl (0 25g), Assay Found C 61 1 , H 7 8, N 4 4% C 31 H 46 CIFN 2 O 5 S1 requires C 61 1 , H 7 6, N 4 6% from 4-amιno-2-fluoro-phenylacetιc acid methyl ester (0 10g) and {2R-(tert- butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- amιno}-propιonaldehyde (0 25g) Intermediate 24 f4-(2R-.tert-Butoxycarbonyl-f2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)- ethyll-amιno.-propylamιno)-3-fluoro-phenyll-acetιc acid methyl ester as a pale yellow gum (0 56g), Assay Found C 61 2, H 7 8, N 4 7% C 31 H 46 CIFN 2 θ 5 Sι requires C 61 1 , H 7 6, N 4 6% from 4-amιno-3-fluoro-phenylacetιc acid methyl ester (0 27g) and {2R-(tert- butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- amιno}-propιonaldehyde (0 66g) Intermediate 25 [4-(2R-(tert-Butoxycarbonyl-f2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)- ethvn-amιno)-propylamιno)-2,3-dιfluoro-phenvn-acetιc acid methyl ester as a colourless oil (0 50g), Assay Found C 59 9, H 7 4 N 4 4% C 31 H 45 CIF 2 N 2 O 5 S1 requires C 59 4, H 7 2, N 4 5% from 4-amιno-2,3-dιfluoro-phenylacetιc acid methyl ester (0 3g) and {2R-(tert- butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- amιno}-propιonatdehyde (0 50g) Intermediate 26 .4-(2R-(tert-Butoxycarbonyl-f2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)- ethyll-amιno}-propylamιno)-5-chloro-2-methoxy-phenyll-acetιc acid methyl ester as a colourless oil (0 04g), c 32 68 cl 2 N 2θ6 Sl MH + 656 from 4-amιno-5-chloro-2-methoxy-phenylacetιc acid, methyl ester (0 05g) and {2R- (tert-butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- amιno}-propιonaldehyde (0 1 g) Intermediate 27 r4-(2-(tert-Butoxycarbonyl-r2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)- ethvH-amιno,-ethylamιno)-2-methyl-phenyi1-acetιc acid methyl ester as a yellow gum C 31 H4 7 CIN 2 O5 MH + 591 from (4-amιno-2-methyl-phenyl)-acetιc acid methyl ester (0 20g) and {2R-(tert- butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- amιπo}-acetaldehyde (0 525g) Intermediate 28 f4-(2-(tert-Butoxycarbonyl-.2R-.tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenvO- ethvπ-amιno)-ethylamιno)-2-tnfluoromethyl-phenvπ-acetιc acid methyl ester as a colourless gum C 31 H 4 F 3 CIN 2 θ 5 MH + 645 from (4-amιno-2-trιfluoromethyl-phenyl)-acetιc acid methyl ester (0 087g) and {2R- (tert-butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- amιno}-acetaldehyde (0 224g) Intermediate 29 f4-(2R-{tert-Butoxycarbonyl-.2R-(tert-butyl-dιmethyl-sιlanyloxyl-2-(3-chloro-phenyl)- ethyll-amιno}-propylamιno)-2-trιfluoromethyl-phenyll-acetιc acid methyl ester as a colourless gum (0 307g) C3 . H44F3CIN 2 O 5 MH + 659 from (4-amιno-2-trιfluoromethyl-phenyl)-acetιc acid methyl ester (0 150g) and {2R- (tert-butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- ammoj-acetaldehyde (0 313g) Intermediate 30 f4-(2-(tert-Butoxycarbonyl-f2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chtoro-phenyl)- ethvH-amιno.-ethylamιno.-2,3-dιfluoro-phenyl1-acetιc acid methyl ester as a colourless gum (0 12g) n m r (CDCI 3 ) d values include -0 11 (s, 3H), 0 03 (3, 3H), 0 88 (s, 9H), 3 56 (s, 2H), 3 70 (s, 3H), 6 35 (t, 1 H), 6 81 (t, 1 H), 7 37 (broad s, 1 H) from (4-amιno-2,3-dιfluoro-phenyl)-acetιc acid methyl ester (0 10g) and {2R-(tert- butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- amιno}-acetaldehyde (0 30g) Intermediate 31 r4-(2R-(tert-Butoxycarbonyl-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)- ethyl1-amιno)-propylamιno)-2,3,6-tnfluoro-phenyll-acetιc acid methyl ester as a colourless gum (0 293g ), n m r (CDCI 3 ) d values include -0 11 (s, 3H), 0 032 (s, 3H), 0 88 (s, 9H), 3 02-3 29 (m, 4H), 3 59 (s, 2H), 3 71 (s, 3H), 6 17 (m, 1 H), from {2R-(tert-Butoxycarbonyl)-[2R-(tert-Butyl-dιmethyl-sιlanyloxy)-2-(3-chloro- phenyl)-ethyl]-amιno}-propιonaldehyde (0 83g) and (4-Amιno-2,3,6-trιfluoro-phenyl)- acetic acid methyl ester (0 33g) Intermediate 32 r4-.2R-(tert-Butoxycarbonyl-r2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl .- ethyll-amιno -propylamιno)-2-chloro-phenyll-acetιc acid methyl ester as a yellow oil (400 mg), from {2R-(tert-butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanoxy)-2-(3- chloro-pheπyl)-ethyl]-amιno}propιonaldehyde (0 36g, 0 8 mmol) and (4-amιno- 2chloro-phenyl)acetιc acid methyl ester (0 23g, 1 19 mmol) Intermediate 33 [4-(2R-{tert-Butoxycarbonyl-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)- ethyn-amιno)-propylamιno)-5-chloro-2-methyl-phenvn-acetιc acid methyl ester as a colorless oil (230 mg) from {2R-(tert-butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanoxy)-2-(3-chloro-phenyl)- ethyl]-amιno}propιonaldehyde (0 35g) and (4-amιno-2-methyl-3-chloro-phenyl)acetιc acid methyl ester (0 26g) Intermediate 34 (4-(2R-{tert-Butoxycarbonyl-r2R-(tertbutyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)- ethyl1-amιno)-propylamιno)-2.6-dιfluoro-phenvoxy)-acetιc acid methyl ester(454 mg), TLC (2 1 hexanes ethyl acetate) Rf 0 6 from (4-amιno-2,6-dιfluoro-phenoxy)-acetιc acid methyl ester (314 mg) and {2R-(tert- butoxycarbonyl)-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro-phenyl)-ethyl]- amιno}-propιonaldehyde (380 mg) Intermediate 35 2-(4-nιtro-2chlorophenyl)-malonιc acid dimethyl ester 3-Chloro-4-fluoronιtobeπzene (1 9g) and dimethylmalonate (1 26 mL) were dissolved in N-methylpyrrolidinone (50mL) Sodium hydroxide (0 92g) was added and the solution heated at 80° for 2 h The reaction was cooled and 1 N hydrochloric acid added The mixture was extracted with ethyl acetate, concentrated and the residue purified by chromatography on silica gel eluting with hexane/ethyl acetate (9 1 ) to give the title compound (2 45 g) Intermediate 36 2-(4 nιtro-2-chlorophenyl )acetιc acid methyl ester 2-(4-nιtro-2chlorophenyl)-malonιc acid dimethyl ester was dissolved in DMSO, then lithium chloride (0 759g), and water (0 15 mL) were added The mixture was heated to 100 °C for 3h The reaction was cooled and the product purified by chromatography on silica gel eluting with hexane/ethyl acetate (9 1 ) to give the title compound as a yellow oil (1 77g) Intermediate 37 (4-Amιno-2-chloro-phenyl)-acetιc acid methyl ester 2-(4 nιtro-2-chlorophenyl )acetιc acid methyl ester was reduced with tin chloride in methanol at reflux for 2 h The solution was poured over ice and neutralized with saturated sodium bicarbonate The mixture was extracted with methylene chloride, dried (MgSO4), and concentrated The oil was purified by silica gel chromatography eluted with hexane/ethyi acetate(9 1 to 8 2) to yield the title compound (0 81 g) 1 H NMR (400 mHz, CDCI 3 ) d 7 0 (d, 1 H), 6 7 (s, 1 H), 6 5 (d, 1 H), 3 74 (s, 2H), 3 68 (s, 3H), 3 63 (s, 2H) Intermediate 38 2-(4-nιtro-5-chloro-2-methyl)phenyl acetic acid methyl ester 4-Chloro-2-fluoro-5-nιtrotoluene (1 Og) and dimethylmalonate (0 61 mL) were dissolved in N-methylpyrrolidmone (40 mL) Sodium hydroxide (0 45g) was added and the solution heated at 80° for 4 h Reaction was cooled and 1 N hydrochloric acid added The mixture was extracted with ethyl acetate and concentrated to give 1 52 g of crude product (96%) The above product was dissolved in DMSO and lithium chloride (0 45 g), and water (0 90 mL) were added The mixture was heated to 100 °C for 4h and allowed to stir at room temperature for 18 h Hydrochloric acid (1 N) was added and the solution extracted with ethyl acetate dried, filtered, concentrated and the residue purified by chromatography on silica gel to give the title compound as an oil (0 53g) Intermediate 39 (4-Amιno-2-chloro-5-methyl-phenyl)-acetιc acid methyl ester (4-nιtro-2-chloro-5-methyl)phenyl acetic acid methyl ester was reduced with tin chloride in ethanol at 70 °C for 1 h The solution was cooled and poured over ice 5 and neutralized with saturated sodium bicarbonate The mixture was extracted with ethyl acetate, dried, and concentrated The resulting oil was purified by silica gel chromatography eluting with hexane/ethyl acetate(9 1 ) to yield the title compound (0 446 g) Analysis by NMR indicated a mixture of methyl and ethyl esters 1 H NMR (400 mHz, CDCI 3 ) d 7 0 9 (s, 1 H), 6 57 (s, 1 H), 4 1 (q), 3 66 (s, 2H), 10 3 46 (d), 2 17 (s, 3H), 1 2 (t) Intermediate 40 2-,4-amιno- 3-trιfluoromethyl-phenyll-malonιc acid methyl ester To a solution of benzylmethyl malonate (0 99 g) in anhydrous N,N- 15 dimethylformamide (50 mL) was added 60% NaH in mineral oil (0 18 g) in portions After 20 mm, 4-fluoro-2-tπfluoromethylnιtrobenzene (1 0 g) in N,N- dimethylformamide (20 mL) was added dropwise via addition funnel Following the addition, the mixture was heated at 90 °C for 3 h The mixture was allowed to cool to ambient temperature, and diluted with water The mixture was extracted with 20 ethyl acetate and the combined organic layers were dried over Na 2 SO 4 , filtered and concentrated to give the intermediate benzyl methyl ester as an orange oil This material was stirred under 1 atmosphere hydrogen gas in 30 mL methanol with 0 20 g 10% Pd/C catalyst for 4 5 h Filtration through a pad of celite and concentration of the filtrate afforded the title compound (340 mg) as a red oil Intermediate 41 r4-(2R-Amιno-propylamιno)-3-trιfluoromethyl-phenvπ-acetιc acid methyl ester A mixture of 2-(4-amιno-3-tπfluoromethyl-phenyl)-malonιc acid methyl ester (356 mg), (2R)-(-)-tert-butyoxycarbonyl-amιno-1 -propιonaldehyde (341 mg) and acetic acid (3 drops) in anhydrous dichloromethane (20 mL) was stirred for 10 mm Sodium triacetoxyborohydride (780 mg) was added, and the mixture was stirred at ambient temperature for 24 h The mixture was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated The residue was purified by chromatography eluting with hexane ethyl acetate (5 1 ) to afford a pale yellow oil Concentration of the relevant fractions gave a material which was dissolved in dichloromethane (40 mL) and trifluoroacetic acid (4 mL) The mixture was stirred at ambient temperature for 3 h, and concentrated The residue was partitioned between aqueous sodium acetate and ethyl acetate The ethyl acetate layer was concentrated to afford a residue which was purified by silica gel chromatography eluting with ethyl acetate methanol (5 1 ) to afford, after concentration of the relevant fractions, the title compound (242 mg) as a yellow oil Cι 3 H 17 N 2 O 2 F 3 MH + 291 Intermediate 42 (4-(2R-f2-(3-Chloro-phenyl)-2R-hvdroxy-ethylamιnol-propylamιno)-3-trιfluoromethyl- phenvD-acetic acid methyl ester A mixture of [4-(2R-amιno-propylamιno)-3-tπfiuoromethyl-phenyl]-acetιc acid methyl ester (255 mg) and (R)-3-chlorostyrene oxide (90 mg) was in πitromethane (4 mL) was heated at 105 °C for 36 h The mixture was allowed to cool to ambient temperature, and concentrated to afford a residue which was purified by silica gel chromatography eluting with hexane ethyl acetate (2 1 ) followed by 1 1 hexanes ethyl acetate to afford after concentration of the relevant fractions the title compound (75 1 mg) as a tan oil C 21 H 24 ClιF 3 N 2 O 3 MH + 445 Intermediate 43 (4-Nιtro-2.6-dιfluoro-phenoxy)-acetιc acid methyl ester A mixture of 4-πιtro-2,6-dιfluoro-phenol (5 08 g, 29 0 mmol) and cesium carbonate (10 3 g, 31 7 mmol) in 100 mL acetonitrile was treated with methyl bromoacetate (3 0 mL, 31 7 mmol) The mixture was heated at reflux for 2 h The mixture was allowed to cool to ambient temperature, and partitioned between water and ethyl acetate The organic layer was separated and dried over sodium sulfate, filtered, and concentrated to afford material which was purified by silica gei chromatography eluting with hexane ethyl acetate (2 1 ) Concentration of the relevant fractions afforded the title compound (6 11 g) as a white solid n m r (CDCI 3 ) d 3 83 (s, 3H), 4 98 (s, 2H), 7 85-7 98 (m, 2H) Intermediate 44 (4-Amιno-2,6-dιfluoro-phenoxy)-acetιc acid methyl ester A slurry of (4-nιtro-2,6-dιfluoro-phenoxy)-acetιc acid methyl ester (737 mg, 2 98 mmol) and 10% palladium on carbon (200 mg) in tetrahydrofuran (40 mL) was stirred under 1 atmosphere of hydrogen gas for 7 h The mixture was flushed with nitrogen, and filtered through a pad of celite to afford the title compound as a pale tan oil (646 mg) that solidified on standing n m r (CDCI 3 ) d 3 68 (bs, 2H), 3 78 (s, 3H), 4 59 (s, 2H), 6 17-6 21 (m, 2H) Example 1 (1-(2-r2-(3-Chloro-phenyl)-2R-hvdroxyl-ethylamιnol-propyl)-2.3-dιhvdro-1 H-ιndol-5- yl)-acetιc acid [1-(2-{tert-Butoxycarbonyl-[2R-(tert-butyl-dιmethyi-sιlanoxy)-2-(3-chloro-phenyl)- ethyl]-amιno}-propyl)-2,3-dιhydro-1 H-ιndol-5-yl]-acetιc acid methyl ester (020g) was dissolved in tetrahydrofuran (5ml) and the solution was treated with 6N hydrochloric acid (5ml) for 72h The solution was evaporated to dryness and the residue purified by chromatography with Sorbsil C60 eluting with the chloroform methanol 0 880 ammonium hydroxide (10 5 1 ) to give the title compound as a yellow solid (0 08g) Assay Found. C 61.0, H 6.5, N 6.8% C 21 H 25 CIN2O 3 . I .25H2O requires C 61.3; H 6.7, N 6.8% n.m.r. (DMSO-d 6 ): d values include 1 05 (m, 3H), 2.61-3.30 (m, 5H), 4 70 (m, 1 H), 6.41 (m, 1 H), 6.85-6.95 (m, 2H), 7.25-7.45 (m, 4H). Similarly prepared were Example 2 ( 1 - ( 2-r2-.3-Chloro-phenyl ) -2R-hvdroxyl-ethylamιno1-propyl)-1 ,2.3,4-tetrahvdro- quιnolin-6-yl)-acetιc acid as a brown solid (0.23g), Assay Found C 65.2, H 6.95; N 6.9% C 22 H 27 CIN 2 O 3 .O 1 H 2 O requires C 65.3, H 6.8; N 6.9% n.m.r. (DMSO-d 6 ): d values include 0.99 (d, 3H), 3.30 (s, 2H), 4.61 (t, 1 H), 6.50 (d, 1 H), 6.73 (s, 1H), 6.81 (dd, 1 H), 7.37 (broad s, 1 H). from [1-(2-{tert-Butoxycarbonyl-[2R-(tert-butyl-dιmethyl-sιlanoxy)-2-(3-chloro- phenyl)-ethyi]-amιno}-propyl)-1 ,2,3,4-tetrahydro-quιnolιn-6-yl]-acetιc acid methyl ester (0.51 g). Example 3 (4-f2R-12-(3-Chioro-phenvπ-2R-hydroxyl-ethylamιnol-propylamino)-2-methyl- phenyQ-acetic acid as a colourless solid (0.08g), Assay Found: C 55.5; H 6.7; N 8.7% C2 0 H 25 CIN 2 O 3 . I H 2 O.O.75NH 4 CI requires C 55.2; H 6.95; N 8.85% n.m.r. (DMSO-d 6 ): d values include 1.06 (d, 3H), 2.11 (s, 3H), 4 62 (t, 1 H), 6.34 (t, 2H), 6.87 (d, 1 H), 7.22-7.50 (m, 4H). from [4-(2R-{tert-Butoxycarbonyl-[2R-(tert-butyl-dimethyl-sιianoxy)-2-(3-chloro- phenyl)-ethyl]-amιno}-propylamιno)-2-methyl-phenyl]-acetιc acid methyl ester (0.2g) Example 4 (4-f2R-f2-(3-Chloro-phenyl)-2R-hvdroxyl-ethylamιno1-propylamino)-3-methyl- phenvD-acetic acid as a colourless solid (0.11 g), Assay Found: C 45.45; H 6 95; N 11.1 % C 20 H 25 CIN 2 O 3 .2.6H 2 O.3.3NH 4 CI requires C 45 3, H 6.9, N 11.2% n.m.r. (DMSO-d 6 ): d values include 1.10 (d, 3H), 2.02 (s, 3H), 4 71 (t, 1 H), 6.49 (d, 1 H), 6.88 (broad d, 2H), 7.21-7.49 (m, 4H). from [4-(2R-{tert-butoxycarboπyl-[2R-(tert-butyl-dιmethyl-silanoxy)-2-(3-chloro- phenyl)-ethyl]-amιno}-propylamιno)-3-methyl-phenyl]-acetic acid methyl ester (0.24g) Example 5 (4-(2R-f2-(3-Chloro-phenyl)-2R-hvdroxyl-ethylamιno1-propylamιno)-2-fluoro-phenyl)- acetic acid as a colourless solid (O.Oδg), Assay Found. C 49.1 , H 5.9, N 9.65% C 19 H 2 2CIFN 2 O 3 O.8H 2 O. I .3NH 4 CI requires C 49.1 ; H 6.25; N 9.9% n.m.r. (DMSO-d 6 ): d values include 1.08 (d, 3H), 4.67 (t, 1 H), 6.26-6.42 (m, 2H), 6.96 (t, 1 H), 7.23-7.49 (m, 4H). from [4-(2R-{tert-butoxycarbonyl-[2R-(tert-butyl-dimethyl-sιlanoxy)-2-(3-chloro- phenyl)-ethyl]-amino}-propylamino)-2-fluoro-phenyl]-acetιc acid methyl ester (0.24g). Example 6 (4-(2R-f2-(3-Chloro-phenyl)-2R-hvdroxyl-ethylamιno1-propylamιno}-3-fluoro-phenyl)- acetic acid as a pale brown foam (0 36g), Assay Found C 56 8, H 5 8 N 7 3% C 19 H 22 CIFN 2 O 3 H 2 O requires C 57 2, H 6 1 , N 7 0% n m r (DMSO-d 6 ) d values include 1 08 (d, 3H), 4 71 (t, 1 H), 6 66 (t, 1 H), 6 79-7 02 (q, 2H), 7 21 -7 51 (m, 4H) from [4-(2R-{tert-butoxycarbonyl-[2R-(tert-butyl-dιmethyl-sιlanoxy)-2-(3-chloro- phenyl)-ethyl]-amιno}-propyiamιno)-3-fluoro-phenyl]-acetιc acid methyl ester (0 50g) Example 7 (4-(2R-f2-(3-Chloro-phenyl)-2R-hvdroxyl-ethylamιno1-propylamιno}-2,3-dιfluoro- phenvD-acetic acid as a colourless solid (0 20g), Assay Found C 37 2, H 6 4, N 11 4% C 19 H 2 ,CIF 2 N 2 θ 3 3H 2 0 3NH 4 CI requires C 37 1 , H 6 2, N 11 9% n m r (DMSO-d 6 ) d values include 1 14 (d, 3H), 5 02 (t 1 H), 6 67 (broad t 1 H), 6 90 (t, 1 H), 7 28-7 60 (m, 4H) from [4-(2R-{tert-butoxycarbonyl-[2R-(tert-butyl-dιmethyl-sιlanoxy)-2-(3-chloro- phenyl)-ethyl]-amιno}-propylamιno)-2,3-dιfluoro-phenyl]-acetιc acid methyl ester (044g) Example 8 (5-Chloro-4-(2R-f2-(3-chloro-phenyl)-2R-hvdroxy-ethylamιno1-propylamιno)-2- methoxy-phenvD-acetic acid dihvdrochloride as a colourless solid (0 006g) n m r (DMSO-d 6 ) d values include 1 04 (s, 3H), 3 68 (s, 3H), 4 65 (t, 1 H), 7 00 (s, 1 H), 7 21-7 35 (m, 4H), 7 39 (s, 1 H) from (5-chloro-[4-(2R-{tert-butoxycarbonyl-[2R-(tert-butyl-dιmethyl-sιlanoxy)-2-(3- chloro-phenyl)-ethyl]-amιno}-propylamιno)- 2-methoxy-phenyl])-acetιc acid methyl ester (0 037g) Example 9 (4-f2-r2-(3-chloro-phenvπ-2R-hvdroxyl-ethylamιno1-ethylamιno)-2-methyl-phenvπ- acetic acid as a colourless solid (0.287g) C19H24CI N2O3 MH + 363 1470 (error 1 6ppm) n m.r. (DMSO-d 6 ) d values include 2 11 (s, 3H), 4 65 (m, 1 H), 6 32 (dd, 1 H), 6 34 (d, 1H), 6 84 (d, 1 H), 7 40 (broad s, 1 H) from 4-(2-{tert-Butoxycarbonyl-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro- phenyl)-ethyl]-amιno}-ethylamιno)-2-methyl-phenyl]-acetιc acid methyl ester (0.549g) Example 10 (4-(2-[2-(3-chloro-phenyl)-2R-hvdroxyl-ethylamιnol-ethylamιno)-2-tπfluoromethyl- phenvD-acetic acid as a yellow solid (0 028g) C 19 H 2 ι CI F 3 N 2 O 3 MH + 417 1208 (error 3.6ppm) n.m.r. (DMSO-d 6 )' d values include 3.54 (s, 2H), 4 68 (m, 1 H), 6 76 (dd, 1 H), 6.84 (d, 1 H), 7.15 (d, 1 H), 7 41 (broad s, 1 H) from [4-(2-{tert-Butoxycarbonyl-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro- phenyl)-ethyl]-amιno}-ethylamιno)-2-trifluoromethyl-phenyl]-acetιc acid methyl ester (0.18g) Example 11 (4-{2-[2-(3-chloro-phenyl)-2R-hvdroxyl-ethylamιnol-ethylamιno)-2.3-dιfluoro-phenyl)- acetic acid from [4-(2-{tert-Butoxycarbonyl-[2R-(tert-butyl-dιmethyl-silanyloxy)-2-(3- chloro-phenyl)-ethyl]-ammo}-ethylamιno)-2,3-difluoro-phenyl]-acetιc acid methyl ester Example 12 (4-(2R-r2-(3-Chloro-phenyl)-2R-hvdroxyl-ethylamιno]-propylamιno}-2,3,6-trifluoro- phenvD-acetic acid from [4-(2R-{tert-Butoxycarbonyl-[2R-(tert-butyl-dιmethyl- silanyloxy)-2-(3-chloro-phenyl)-ethyl]-amιπo}-propylamιno)-2,3,6-trifluoro-phenyl]- acetic acid methyl ester Example 13 .2-Chloro-4-(2R-([2-(3-chloro-phenyl)-2R-hvdroxy-ethyl]-amιno)-propylamιno)- phenyll-acetic acid (15mg) as a white solid 1 H NMR (300 mHz, DMSO-de) d 7 4(s,1 H), 7.3 (m,3H), 7.0 (d, 1 H), 6.6 (s, 1 H), 6.5 (d, 1 H), 5 8 (bs, 1 H), 4 7 (m, 1 H), 1.1 (d, 3H). HPLC analysis (C18 column) 1 mL/mιn, 20-50% acetoπιtπle/water( 0.1 % TFA) T R = 17.5 mm from [4-(2R-{tert-Butoxycarbonyl-[2R-(tert-butyl-dimethyl-silaπyloxy)-2-(3-chloro- phenyl)-ethyl]-amino}-propylamιno)-2-chloro-phenyl]-acetιc acid methyl ester Example 14 f5-Chloro-4-.2R-(f2-(3-chloro-phenyl)-2R-hvdroxy-ethyll-amιno)-propylamιno)-2- methyl-phenyll-acetic acid methyl ester as a white solid (110 mg) Analysis: Calc. for C 2 oH2 4 N 2 0 3 CI 2 (0.25 H 2 O) : C, 56.55, H, 5.69, N, 6.59% Found- C, 56 49, H, 5.99, N, 6.56% 36 C 20 H 24 N 2 O 3 CI 2 MH + 411 from [4-(2R-{tert-Butoxycarbonyl-[2R-(tert-butyl-dιmethyl-sιlanyloxy)-2-(3-chloro- phenyl)-ethyl]-amιno}-propylamιno)-5-chloro-2-methyl-phenyl]-acetιc acid methyl ester Example 15 (4- 2R-r2-.3-Chloro-phenvπ-2R-hvdroxy-ethylamιno1-propylamιno)-2,6-dιfluoro- phenoxy)-acetιc acid as an off-white solid (46 mg) mp 105 °C (dec) π m r (CDCI 3 ) d 1 34 (d, 3H), 3 05-3 57 (m, 5H), 4 30 (s, 2H), 5 00 (dd, H), 6 20- 6 30 (m, 2H), 7 28-7 40 (m, 3H), 7 47 (s, 1 H) from (4-{2R-{tert-butoxycarbonyl-[2R-(tertbutyl-dιmethyl-sιlanyloxy)-2-(3-chloro- phenyl)-ethyl]-amιno}-propylamιno)-2,6-dιfluoro-phenyoxy)-acetιc acid methyl ester (451 mg) Example 16 (4-(2R-f2-(3-Chloro-phenyl)-2R-hvdroxy-ethylamιnol-propylamιnoV3-tπfluoromethyl- phenvD-acetic acid A solution of (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxy-ethylamιno]-propylamιno}-3- tπfluoromethyl-phenyl)-acetιc acid methyl ester (75 1 mg) in tetrahydrofuran (4 mL) and 6N aqueous hydrochloric acid (4 mL) was stirred at ambient temperature for 18 h The residue was concentrated and lyophilized to afford a residue which was puπfied by silica gel chromatography eluting with chloroform methanol concentrated ammonium hydroxide (30 15 1 ) to afford after concentration of the relevant fractions the title compound (58 9 mg) as a white solid mp 161 -163 °C Assay Found C 54 5, H, 5 2, N, 6 1 % C 2 _H 22 CI .F 3 N 2 O 3 0 5H 2 0 requires C 54 6, H, 5 3, N, 6 4% Example 17 (4-(2R-f2-(3-Chloro-phenyl)-2R-hvdroxy-ethylamιno1-propylamιno)-2-trιfluoromethyl- phenvQ-acetic acid A solution of (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxy-ethylamιno]-propylamιno}-2- tπfluoromethyl-phenyl)-acetιc acid methyl ester (290 mg) in tetrahydrofuran (4 mL) and 6N aqueous hydrochloric acid (4 mL) was stirred at ambient temperature for 18 h The residue was concentrated and lyophilized to afford a residue which was purified by silica gel chromatography eluting with chloroform methanol concentrated ammonium hydroxide (30 15 1 ) to afford after concentration of the relevant fractions the title compound (122 mg) as a white solid C 2 oH22CI 1 F 3 N2θ3 MH + 431 134 (error 2 2ppm) n m r (CDCI 3 ) d values include 1 085 (d, 3H), 2 85 (m, 2H), 2 885-3 12 (m, 3H), 3 545 (s, 2H) 4 705 (m, 1 H), 6 045 (bt, 1 H), 6 765 (dd, 1 H), 6 855 (d, 1 H), 7 265-7 4 (m, 3H) TABLETS FOR ORAL ADMINISTRATION Tablets may be prepared by the normal methods such as direct compression or wet granulation The tablets may be film coated with suitable film forming materials, such as hydroxypropyl methylcellulose, using standard techniques Alternatively the tablets may be sugar coated Direct Compression Tablet mg/tablet (i) Active Ingredient 4 688 Calcium Hydrogen Phosphate BP * 83 06 Croscarmellose Sodium NF 1 8 Magnesium Stearate BP 0_ Compression weight 90 0 * of a grade suitable for direct compression The active ingredient is passed through a 60 mesh sieve, blended with the calcium hydrogen phosphate, croscarmellose sodium and magnesium stearate The resultant mix is compressed into tablets using a Manesty F3 tablet machine fitted with 5 5mm, flat bevelled edge punches mg/tablet (n) Active Ingredient 0 31 Anhydrous Lactose USNF 131 99 Pregelatinised Starch USNF 7 0 Magnesium Stearate BP 0 7 Compression weight 140 0 The active ingredient is passed through a 60 mesh sieve, and blended with the lactose, pregelatinised starch and magnesium stearate The resultant mix is compressed into tablets using a Manesty F3 tablet machine fitted with 7 5mm normal concave punches SYRUP This may be either a sucrose or sucrose free presentation A Sucrose Syrup mq/5ml dose Active Ingredient 2 5 Sucrose BP 2750 0 Glycerine BP 500.0 Buffer ) Flavour ) Colour ) as required Preservative ) Purified Water BP to 5.0ml The active ingredient, buffer, flavour, colour and preservative are dissolved in some of the water and the glycerine is added The remainder of the water is heated to dissolve the sucrose and is then cooled The two solutions are combined, adjusted to volume and mixed The syrup is clarified by filtration B. Sucrose-free Syrup mq/5ml dose Active Ingredient 2.5 Hydroxypropyimethylcellulose USP (viscosity type 4000) 22.5 Buffer ) Flavour ) Colour ) as required Preservative ) Sweetener ) Purified Water BP to 5.0ml The hydroxypropyimethylcellulose is dispersed in hot water, cooled and then mixed with an aqueous solution containing the active ingredient and the other components of the formulation The resultant solution is adjusted to volume and mixed The syrup is clarified by filtration INJECTION FOR INTRAVENOUS ADMINISTRATION μq/ml (i) Active Ingredient 800 Dilute Hydrochloric Acid BP to pH 3 5 Sodium Chloride Injection BP to 1 ml The active ingredient is dissolved in a suitable volume of Sodium Chloride Injection BP, the pH of the resultant solution is adjusted to pH3 5 with dilute hydrochloric acid BP then the solution is made to volume with sodium chloride injection BP and thoroughly mixed The solution is filled into Type I clear glass 5ml ampoules which are sealed under a headspace of air, by fusion of the glass then sterilised by autoclaving at 120^ for not less than 15 minutes ug/ml (II) Active ingredient 56 2 Sodium Chloride BP as required Water for Injection BP to 1 0ml Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted, using acid or alkali, to that of optimum stability and/or facilitate solution of the active ingredient Alternatively, suitable buffer salts may be used The solution is prepared, clarified and filled into appropriate size ampoules sealed by fusion of the glass The injection is sterilised by heating in an autoclave using one of the acceptable cycles Alternatively, the solution may be sterilised by filtration and filled into sterile ampoules under aseptic conditions The solution may be packed under an inert atmosphere of nitrogen or other suitable gas SUPPOSITORY FOR RECTAL ADMINISTRATION Active ingredient 49 0 mg Witepsol * H15 to 1 0g *a proprietary grade of Adeps Solidus Ph.Eur A suspension of the active ingredient in molten Witepsol is prepared and filled using suitable machinery, into 1 g size suppository moulds The compounds of Examples 7, 8 and 15 were tested for beta-3-adrenoceptor activity using above described Method 1 with the following results Test Method EPMR Ex 7 Ex 8 Ex 15 Method 1 0 2 04 60 The protective effect of the compound of Example 7 was measured as described in above Method 2 and an ED 5 o of 0 003mg/kg was obtained

Claims: CLAIMS A compound of the general formula (I) (I) wherein R 1 represents an aryl group optionally substituted by one or more substituents selected from halogen, hydroxy, C-j -galkoxy, C-μ aikyl, nitro, cyano, hydroxymethyl and trifluoromethyl, R 2 represents hydrogen or C 1-6 alkyl, R 3 represents a group A where the ring is substituted by one to four further substituents selected from C - 6 alkyl, halogen, trifluoromethyl, and d. 6 alkoxy, or R 3 represents a group B where the aromatic ring is optionally substituted by up to three further substituents selected from Cι. 6 alkyl, halogen, trifluoromethyl, and C t ^alkoxy, R 4 represents hydrogen, or Cι. 6 alkyl, R 5 represents ZCH2CO2H wherein Z represents a bond, or O, Y represents (CH 2 ) n where n is 1 -3, and physiologically acceptable derivatives thereof 2 A compound as claimed in claim 1 wherein R 1 represents a phenyl group substituted by a chlorine atom Iocated in the meta position 3 A compound as claimed in claim 1 or claim 2 wherein R 2 is methyl or H 4 A compound as claimed in any one of claims 1 to 3 where R 3 is group A substituted by one or more substituents selected from halogen, methyl, trifluoromethyl, and methoxy 5 A compound as claimed in any one of claims 1 to 3 where R 3 is group B, n is 1 or 2, and the aromatic ring is unsubstituted 6 A compound as claimed in any one of claims 1 to 5 where R . 4 is hydrogen or methyl 7 A compound as claimed in claim 1 where R 1 represents phenyl substituted by a chlorine atom Iocated in the meta position, R2 represents hydrogen or methyl, R3 represents a group A and is substituted by one or more groups selected from halogen, methyl, trifluoromethyl, and methoxy, R 4 represents hydrogen or methyl, R 5 represents CH2CO2H, and physiologically acceptable derivatives thereof 8 (1 -{2-[2-(3-chloro-ρhenyl)-2R-hydroxyl-ethylamιno]-propyl}-2,3-dιhydro-1 H- ιndol-5-yl)-acetιc acid, (1-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propyl}-1 ,2,3,4-tetrahydro- quιnolιn-6-yl)-acetιc acid, (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2-methyl-phenyl)- acetic acid, (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-3-methyl-phenyl)- acetic acid, (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2-fluoro-phenyl)- acetic acid, (4-{2R-[2-(3-chlσro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-3-fluoro-phenyl)- acetic acid, (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2,3-dιfluoro- phenyl)-acetιc acid, (5-Chloro-4-{2R-[2-(3-chloro-phenyl)-2R-hydroxy-ethylamιno]-propylamιno}-2- methoxy-phenyl)-acetιc acid, (4-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-ethylamιno}-2-methyl-phenyl)- acetic acid, (4-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-ethylamιno}-2,3-dιfluoro-phenyl)- acetic acid, (4-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-ethylamιπo}-2-tπfluoromethyl- phenyl)-acetιc acid, (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2,6-dιfluoro- phenyl)-acetιc acid, (4-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-ethylamιno}-2,3,6-tπfluoro- phenyl)-acetιc acid, (4-{2-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylamιno]-propylamιno}-2-tπfluoromethyl- phenyl)-acetιc acid, (4-{2R-[2-(3-Chloro-phenyl)-2R-hydroxyl-ethylamιno]-ρropylamιno}-2,3,6-tπfluoro- phenyl)-acetιc acid, [2-Chloro-4(2-{[2-(3-chloro-phenyl)-2R-hydroxy-ethyl]-amιno}-propylamιno)-phenyl]- acetic acid, [5-Chloro-4-(2R-{[2-(3-chloro-phenyl)-2R-hydroxy-ethyl]-amιno}-propylamιno)-2- methyl-pheπyl]-acetιc acid, (4-{2R-[2-(3-Chloro-phenyl)-2R-hydroxy-ethyiamιno]-propylamιno}-2,6-dιfluoro- phenoxy)-acetιc acid, (4-{2R-[2-(3-Chloro-phenyl)-2R-hydroxy-ethylamιno]-propylamιno}-3-trιfluoromethyl- phenyl)-acetιc acid, or a physiologically acceptable derivative thereof 9 (4-{2R-[2-(3-chloro-phenyl)-2R-hydroxyl-ethylammo]-propylamιno}-2,3- dιfluoro-phenyl)-acetιc acid, or a physiologically acceptable derivative thereof 5 10 A compound according to any one of Claims 1 to 9 for use in therapy 11 A method of treatment of a mammal, including man, suffering from a condition susceptible of amelioration by an atypical beta-adrenoceptor agonist comprising administration of an effective amount of a compound according to any one of claims 1 to 9 or a physiologically acceptable derivative thereof 10 12 The use of a compound according to any one of claims 1 to 9 or a physiologically acceptable derivative thereof, for the manufacture of a medicament for the treatment of a condition susceptible of amelioration by an atypical beta- adrenoceptor agonist 13 A pharmaceutical composition comprising a compound according to any one 15 of claims 1 to 9 or a physiologically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers 14 A pharmaceutical composition which comprises a compound according to any one of claims 1 to 9 and a non-steroidal anti-inflammatory drug, together with one or more pharmaceutically acceptable carriers 20 15 A process for preparing a compound of formula (I) as claimed in claim 1 , or a physiologically acceptable derivative thereof which comprises (A), compounds of formula (I) may be prepared by reaction of a compound of formula (la) R 2 R a R (la) wherein R 1 , R 2 , and, are as defined as for formula (I), R 3 represents R 3 where the acidic group is protected by an alkyl ester, and R a and R b are protecting groups, by deprotection of the protecting groups (B), compounds of formula (I) may be prepared by reaction of a compound of formula (II) with a compound of formula (III) wherein R 1 , R 2 , R 3 ,R a , and R b are as defined above, in the presence of a reducing agent, followed by removal of the protecting groups

Inventors: FOXTON MICHAEL WALTER, GREEN RICHARD HOWARD, FOXTON, MICHAEL, WALTER, GREEN, RICHARD, HOWARD
Applicants: FOXTON MICHAEL WALTER, GLAXO GROUP LTD, GREEN RICHARD HOWARD, FOXTON, MICHAEL, WALTER, GLAXO GROUP LIMITED, GREEN, RICHARD, HOWARD
Application year: 1996
Main classification: C07C229
IPC codes: A61K31, A61K45, A61P1, A61P3, A61P9, A61P27, A61P43, C07C217, C07C229, C07D209, C07D215